Bloodline

Home
About
Call for Papers
Free Membership
Search


Educational Features

Image Atlas
Case Studies
Private Lectures
Conference Reviews
Journal Articles
Book Reviews
Glossary


Resources

Conference Calendar
Grants & Fellowships
Hematology Links
BMT Reviews
Classifieds


Specialties

BMT/Stem Cell
Cord Blood
Thrombosis
Hemostasis
Laboratory
Malignancies
Pediatrics
Red Cell Disorders
Infections
Transfusion Medicine
Veterinary


News

Hematology News
BloodLink Newsletter
Blood News Update


Discussion

Today's Discussion
Create New Topic
List by Topic

Members

Join Now
Login

websel.gif:

toprated.gif:

Blood and Marrow Transplantation Reviews: Volume 10, Issue 1

INTRODUCTION

by John R. Wingard, MD Editor-in-Chief

The major challenges facing the clinician caring for patients undergoing hematopoietic cell transplantation are the control of graft-versus-host disease and opportunistic infections. With the development of effective strategies to control cytomegalovirus infection, today invasive fungal infections are the leading opportunistic infectious pathogens after HCT. It is, therefore, fitting that the featured topic of this issue addresses the formidable challenges posed by this posttransplantation complication. At the Tandem Transplant Meetings in March [2000], a satellite symposium was held to discuss a variety of issues about fungal infections after allogeneic stem cell transplantation. This symposium was sponsored by Fujisawa Healthcare through an unrestricted educational grant. The transcript of this symposium is the featured topic in this issue. In the initial presentation, I reviewed the risk factors for invasive fungal infections and the epidemiologic shifts in fungal pathogens that we have witnessed during the past decade. Dr. Brown then discussed pharmacologic and immunologic approaches to antifungal prophylaxis. Dr. Einsele addressed the formidable task of early detection of invasive fungal infection and discussed new rapid diagnostic techniques. In conclusion, Dr. Cagnoni presented recent clinical trial data as to the use of the lipid formulations of amphotericin B and discussed the exciting promise of new triazoles and a new class of antifungal agents, the echinocandins, which are currently in clinical trials. This symposium offers an up-to-date review of the current status and promising new diagnostic and treatment modalities that will likely become available to transplant clinicians in the near future.

To download the full issue in PDF format, click the link below.

pdficon.gif: BMTR Volume 10, Issue 1


sm_cjpLogo.gifCopyright 1995-2010 - Carden Jennings Publishing Co., Ltd. All rights reserved. The material available at this site is for educational purposes only and is NOT intended for any diagnostic, clinically related, or other purpose. Carden Jennings Publishing Co., Ltd., assumes no responsibility for any use or misuse of this material and makes no warranty or representation of any kind with respect to the material available at this site.

Related Content